Compare Stocks: HOWL, OKYO, ATRA, and SERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$9.55 +1.8%	$9.33	$3.92 ▼ $19.15	$95.88M	0.12	738,547 shs	9,640 shs
HOWL Werewolf Therapeutics	$0.91 +112.0%	$0.38	$0.27 ▼ $2.38	$44.44M	0.29	2.48 million shs	249.27 million shs
OKYO OKYO Pharma	$1.54 +1.3%	$1.56	$1.34 ▼ $3.20	$80.82M	0.04	158,251 shs	8,053 shs
SERA Sera Prognostics	$2.15 +2.4%	$1.98	$1.56 ▼ $3.95	$84.19M	0.96	51,449 shs	8,883 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-2.29%	+10.22%	+8.69%	-4.29%	-20.24%
HOWL Werewolf Therapeutics	+5.35%	+11.71%	+18.79%	-2.80%	-65.23%
OKYO OKYO Pharma	+0.66%	+0.66%	+5.56%	-6.75%	-38.21%
SERA Sera Prognostics	+5.53%	+4.48%	-7.49%	+1.45%	-6.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$9.55 +1.8%	$9.33	$3.92 ▼ $19.15	$95.88M	0.12	738,547 shs	9,640 shs
HOWL Werewolf Therapeutics	$0.91 +112.0%	$0.38	$0.27 ▼ $2.38	$44.44M	0.29	2.48 million shs	249.27 million shs
OKYO OKYO Pharma	$1.54 +1.3%	$1.56	$1.34 ▼ $3.20	$80.82M	0.04	158,251 shs	8,053 shs
SERA Sera Prognostics	$2.15 +2.4%	$1.98	$1.56 ▼ $3.95	$84.19M	0.96	51,449 shs	8,883 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-2.29%	+10.22%	+8.69%	-4.29%	-20.24%
HOWL Werewolf Therapeutics	+5.35%	+11.71%	+18.79%	-2.80%	-65.23%
OKYO OKYO Pharma	+0.66%	+0.66%	+5.56%	-6.75%	-38.21%
SERA Sera Prognostics	+5.53%	+4.48%	-7.49%	+1.45%	-6.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	-0.52% Downside
HOWL Werewolf Therapeutics	2.14	Hold	$4.00	337.49% Upside
OKYO OKYO Pharma	2.40	Hold	$5.67	267.97% Upside
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	155.81% Upside

Current Analyst Ratings Breakdown

Latest HOWL, OKYO, ATRA, and SERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	OKYO OKYO Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/13/2026	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00
6/17/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/16/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
6/4/2026	SERA Sera Prognostics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$120.77M	0.79	$4.85 per share	1.97	($3.69) per share	-2.59
HOWL Werewolf Therapeutics	$1.88M	23.64	N/A	N/A	$0.34 per share	2.69
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A
SERA Sera Prognostics	$80K	1,052.43	N/A	N/A	$1.52 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	6.82	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
OKYO OKYO Pharma	-$8.95M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	-$31.93M	-$0.67	N/A	N/A	N/A	-47,475.72%	-46.71%	-34.06%	N/A

Latest HOWL, OKYO, ATRA, and SERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.1542	-$0.18	-$0.0258	-$0.18	$0.07 million	$0.03 million
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.98	1.98
HOWL Werewolf Therapeutics	N/A	2.91	2.91
OKYO OKYO Pharma	N/A	2.43	2.43
SERA Sera Prognostics	N/A	1.98	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
HOWL Werewolf Therapeutics	64.84%
OKYO OKYO Pharma	2.97%
SERA Sera Prognostics	54.64%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
HOWL Werewolf Therapeutics	23.60%
OKYO OKYO Pharma	40.46%
SERA Sera Prognostics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	10.04 million	5.90 million	No Data
HOWL Werewolf Therapeutics	40	48.60 million	37.13 million	Optionable
OKYO OKYO Pharma	7	52.48 million	31.25 million	Not Optionable
SERA Sera Prognostics	120	39.16 million	34.73 million	Optionable

HOWL, OKYO, ATRA, and SERA Headlines

Recent News About These Companies

Sera Prognostics, Inc.: Sera Prognostics Appoints Scott Gleason Chief Financial Officer

August 20 at 1:51 PM | finanznachrichten.de

Sera (SERA) Q2 2026 Earnings Call Transcript

August 19 at 10:58 PM | finance.yahoo.com

Sera Prognostics appoints Scott Gleason as CFO, effective Aug. 31

August 19 at 10:58 PM | msn.com

SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

August 19 at 4:30 PM | prnewswire.com

Sera Prognostics, Inc. Q2 2026 Earnings Call Summary

August 14, 2026 | finance.yahoo.com

Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2026 Financial Results

August 13, 2026 | finanznachrichten.de

Sera Prognostics Hits Key Milestones in Second Quarter 2026: Expanding Commercial Engagements and Unlocking Policy Momentum

August 12, 2026 | news.themarketisopen.comN

Sera Prognostics Q2 Earnings Call Highlights

August 12, 2026 | marketbeat.com

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

August 12, 2026 | seekingalpha.com

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

August 12, 2026 | aol.comA

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

August 12, 2026 | marketbeat.com

Sera Prognostics (SERA) Projected to Post Quarterly Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026

July 29, 2026 | prnewswire.com

Sera Prognostics (SERA) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE

July 9, 2026 | prnewswire.com

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

June 30, 2026 | prnewswire.com

SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH

June 24, 2026 | prnewswire.com

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

June 23, 2026 | prnewswire.com

All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy

June 19, 2026 | zacks.com

Sera Prognostics (NASDAQ:SERA) CFO Sells $11,315.20 in Stock

June 11, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, OKYO, ATRA, and SERA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$9.55 +0.17 (+1.81%)

As of 01:03 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Werewolf Therapeutics NASDAQ:HOWL

$0.91 +0.48 (+112.04%)

As of 01:10 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

OKYO Pharma NASDAQ:OKYO

$1.54 +0.02 (+1.32%)

As of 12:53 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Sera Prognostics NASDAQ:SERA

$2.15 +0.05 (+2.38%)

As of 01:13 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, OKYO, ATRA, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, OKYO, ATRA, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, OKYO, ATRA, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, OKYO, ATRA, and SERA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Werewolf Therapeutics NASDAQ:HOWL

OKYO Pharma NASDAQ:OKYO

Sera Prognostics NASDAQ:SERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, OKYO, ATRA, and SERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, OKYO, ATRA, and SERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, OKYO, ATRA, and SERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, OKYO, ATRA, and SERA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Werewolf Therapeutics NASDAQ:HOWL

OKYO Pharma NASDAQ:OKYO

Sera Prognostics NASDAQ:SERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools